Copper outlook for 2026

Market watchers expect many of the forces that drove copper through 2025 to persist.

Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.

Copper demand is projected to grow as the global energy transition accelerates.

“A huge amount of this tightness has to do with US tariff concerns,” she said.

China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.

Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.

A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.

1. Avidity Biosciences (NASDAQ:RNA)

Year-over-year gain: 143.8 percent
Market cap: US$10.87 billion
Share price: US$72.14

Avidity Bioscience is a biopharma firm developing a new form of RNA therapy called antibody oligonucleotide conjugates (AOC) that target the genes causing rare muscle diseases.

Through its proprietary AOC platform, Avidity developed programs for three rare muscle diseases: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy. The company is also working to expand its pipeline into cardiology and immunology.

In October 2025, Avidity entered into a definitive agreement to be acquired by Novartis (NYSE:NVS), which will include the company’s late-stage neuromuscular programs (AOC 1001, 1020, 1044) and the AOC platform, for US$12 billion.

Avidity’s early-stage precision cardiology programs will spin off into a new public company prior to closing in H1 2026. The spin-off will also have rights to use and develop the AOC platform for cardiology applications.

2. Wave Life Sciences (NASDAQ:WVE)

Year-over-year gain: 36.52 percent
Market cap: US$3.13 billion
Share price: US$17.12

Wave Life Sciences is another clinical-stage firm focused on unlocking insights from human genetics to deliver RNA-based medicines. The company’s PRISM platform is targeting both rare and prevalent disorders. Its pipeline includes clinical programs for Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program for WVE-007 in obesity.

Wave Life Sciences advanced its PRISM RNA platform across multiple programs in 2025. It is also performing a Phase 1 trial testing its WVE-007 obesity candidate, which is an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design.

In December, the company reported positive interim data from the WVE-007 trial, which showed that a single dose resulted in sustained Activin E reduction, supporting infrequent dosing. Target engagement updates and body composition readouts are planned for Q1 2026.

3. UniQure (NASDAQ:QURE)

Year-over-year gain: 33.15 percent
Market cap: US$1.47 billion
Share price: US$23.86

UniQure is a gene therapy company focused on patients with severe medical needs. In November 2022, the US Food and Drug Administration (FDA) approved the company’s gene therapy Hemgenix (etranacogene dezaparvovec), which is the world’s first gene therapy for hemophilia B.

Today, uniQure’s proprietary gene therapy pipeline includes treatments for patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS and Fabry disease.

Its gene therapy pipeline advanced in 2025, with positive Phase I/II topline data for Huntington’s disease candidate AMT-130 showing 75 percent slowing of disease progression at three years via cUHDRS, alongside 60 percent functional capacity preservation.

While data from the Phase I/II study led the FDA to grant AMT-130 breakthrough therapy designation in April, in December the agency told UniQure it believes the data may not be adequate to support a pre-biologics license application under the accelerated approval pathway. The company is pursuing a follow-up meeting.

4. Stoke Therapeutics (NASDAQ:STOK)

Year-over-year gain: 186.96 percent
Market cap: US$1.81 billion
Share price: US$31.74

Stoke Therapeutics is another biotech company with a focus on developing RNA medicine. With its proprietary research platform TANGO, which stands for targeted augmentation of nuclear gene output, the company is developing antisense oligonucleotides to selectively restore protein levels.

Stoke’s first product candidate, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe form of genetic epilepsy. The company is also developing STK-002 for the treatment of autosomal dominant optic atrophy, an inherited optic nerve disorder.

Both candidates advanced in 2025, with STK-001 enrolling patients in Phase 3 after positive long-term data showed seizure reductions and cognitive gains. Likewise, STK-002’s clinical development program is being informed by results, presented in October, of a Phase 1 two year natural history study on the disease progression of autosomal dominant optic atrophy.

Investor Insight

E-Power Resources offers investors high-grade exposure to the rapidly expanding flake graphite sector through one of Québec’s most promising districts. With a strategic land position, near-surface discoveries, and a leadership team experienced in exploration and capital markets, E-Power is positioned to help supply North America’s critical battery materials chain.

Overview

E-Power Resources (CSE:EPR) is a Montréal-based company focused on advancing its flagship Tetepisca graphite property in Québec’s North Shore region. The company’s mission is to delineate and develop a high-grade, near-surface flake-graphite resource capable of supplying future North American battery-anode demand.

Since entering the Tetepisca district in 2019, E-Power has systematically advanced its project from regional geophysics to mapping, sampling, drilling and metallurgical testing. This disciplined exploration pipeline has confirmed the presence of district-scale, high-purity graphite mineralization within the same geological sequence that hosts neighboring deposits such as Focus Graphite’s Lac Tetepisca and Nouveau Monde Graphite’s Uatnan, which together hold more than 120 million tons (Mt) measured + indicated at approximately 14 percent Cg.

Graphite demand is accelerating globally as electric-vehicle production and energy-storage capacity expand. Québec’s hydroelectric grid, pro-mining policy environment, and rapidly developing anode-manufacturing infrastructure make it a world-class jurisdiction for low-carbon graphite development. Within this setting, E-Power’s land position, grade profile and technical results uniquely position the company to become a core participant in Canada’s graphite-to-battery supply chain.

Company Highlights

• Flagship project in Québec’s premier graphite district: 100-percent-owned Tetepisca Property, 234 contiguous claims covering ≈ 12,840 ha, the largest land position in the district
• Exceptional grades: 2025 surface sampling returned up to 68.7 percent Cg (carbon in graphite form) at the Graphi-Centre target, among the highest reported globally
• High-purity metallurgy: 2024 bulk sampling produced concentrates grading up to 96.4 percent Cg, validating commercial potential.
• Strategic infrastructure advantage: ~220 km from Baie-Comeau and within trucking distance of a planned 200,000 tons per year (tpy) graphite-anode facility, anchoring Québec’s battery-materials hub.
• Surging Market Demand: With global battery production accelerating, the graphite market is forecast to soar, positioning E-Power to benefit from one of the most dynamic growth trends in the energy materials sector.
• Led by Experience: Backed by a strong, technically skilled management team, E-Power is strategically positioned to advance North American graphite independence and capture growing demand in the energy transition economy.

Key Project

Tetepisca Graphite Project

The Tetepisca graphite property is approximately 220 km north of Baie-Comeau, covering 234 contiguous claims (~12,840 ha) in the heart of the Tetepisca Graphite District (TGD). The property is 100-percent-owned by E-Power and hosts the same graphitic metasedimentary units that define the district’s producing and feasibility-stage assets.

District-Scale Opportunity

The TGD is an emerging flake-graphite camp that now hosts more than 120 Mt of measured and indicated resources averaging ~14 percent Cg across nearby projects such as Nouveau Monde Graphite’s Uatnan and Focus Graphite’s Lac Tetepisca deposits.

E-Power controls the largest contiguous land position in the district, strategically covering the same graphitic metasedimentary horizons that host these deposits. The district’s proximity to the planned 200,000 tpy graphite-anode facility in Baie-Comeau creates a unique alignment of resource, infrastructure and processing capability, positioning E-Power as a potential key upstream feed source for Québec’s integrated graphite-to-anode supply chain.

2024–2025 Exploration Results

E-Power’s work since 2021 has validated the property’s high-grade, near-surface potential.

• The 2025 Phase 1 program returned grab samples up to 68.7 percent Cg at the Graphi-Centre target, one of the highest surface graphite grades reported globally.
• New discoveries on the northern claim block (N3 and N4 targets) yielded multiple samples exceeding 20 percent Cg, extending graphite mineralization across more than 330 meters of strike within continuous conductive trends.
• The Syndicate Trend, a 12 km linear conductor in the southwest, produced a new showing with grades of 54.7 percent Cg within a broader corridor that includes a historical drill intercept of 12.74 percent Cg over 9.55 meters.
• Metallurgical test work from 2024 bulk sampling confirmed high-purity concentrates of up to 96.4 percent Cg, with additional mineralogy and flake-size distribution studies underway to define commercial product potential.

E-Power’s 2025–2026 work program will focus on advancing the Tetepisca property toward an initial resource estimate. Key activities include expanded fieldwork and metallurgical testing at the Graphi-Centre, Captain Cosmos and Syndicate showings; follow-up ground and drone-borne geophysical surveys to refine drill targets; and a focused drilling campaign designed to define near-surface, high-grade graphite zones. In parallel, the company is initiating early environmental baseline and access studies to support future development and potential partnerships within Québec’s growing graphite-to-anode supply chain.

Management Team

Jean-Michel Gauthier – Chief Executive Officer

Jean-Michel Gauthier contributes significant expertise in capital markets, corporate development and strategic positioning within the resource sector. His focus will be on ensuring the optimal deployment of capital and maximizing the inherent value of the Tetepisca Project as it advances through key de-risking stages.

Mark Billings – Chairman of the Board

Mark Billings is a highly respected finance professional in the Canadian resource sector, bringing extensive investment banking and corporate finance experience. His prior roles, including VP corporate finance at Desjardins Securities, provide a crucial foundation for guiding E-Power’s capital formation and strategic financing plans necessary for the Tetepisca Project’s development phases.

Jamie Lavigne – Chief Operating Officer

Jamie Lavigne is a professional economic geologist with over 30 years of experience in exploration and mine development. He has worked with major Canadian and Australian mining companies and several junior explorers and operates his own consulting firm. Lavigne holds a B.Sc. from Memorial University and an MSc. from the University of Ottawa. He is a member of L’Ordre des Géologues du Québec and the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists.

Paul Haber – Chief Financial Officer and Corporate Secretary

Paul Haber brings over 20 years of experience in corporate finance and capital markets. He has served as CFO, board member, and audit chair for numerous public and private companies, including XTM (CSE:PAID), South American Silver (TSX:SAC), and Migao Corporation (TSX:MGO). A CPA and CA, Haber began his career at Coopers & Lybrand and holds an Honours B.A. in Management from the University of Toronto. He also holds a Chartered Director designation from the DeGroote School of Business and the Conference Board of Canada.

Christian Falk – Advisory Board Member

European cannabis legalization and international growth

2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.

This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.

The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.

Investor takeaway

2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.

“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.

Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.

While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.

Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.